KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to KalVista Pharmaceuticals 8-month Fiscal Year 2025 Financial Results and Corporate Update Conference Call.
Kalvista Pharmaceuticals Inc. (KALV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | SilverArc Capital Devesh Gandhi | 2,876,407 | $57,902,073 | +19% | 5.91% |
| 2. | Spruce Street Capital Alex Rosen And Simon Basseyn | 897,681 | $18,070,319 | +132% | 4.34% |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 286,046 | $5,758,106 | 0.04% | |
| 4. | ExodusPoint Capital Michael Gelband | 177,274 | $3,568,526 | +784% | 0.03% |
| 5. | Walleye Capital Will England | 79,666 | $1,603,677 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.42 | 25,000 | $235,500.00 | 5,303,985 | 2025-04-09 | Filing | |
| $9.33 | 61,700 | $575,661.00 | 5,278,985 | 2025-02-13 | Filing | |
| $9.23 | 100,000 | $923,000.00 | 5,217,285 | 2025-02-12 | Filing | |
| $9.18 | 26,703 | $245,133.54 | 5,117,285 | 2025-02-11 | Filing | |
| $9.14 | 4,137 | $37,812.18 | 5,090,582 | 2025-02-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.71 | 3,322 | $88,730.62 | 466,375 | 2026-05-12 | Filing | |
| $20.22 | 2,686 | $54,300.98 | 142,547 | 2026-04-17 | Filing | |
| $20.22 | 1,862 | $37,642.75 | 51,391 | 2026-04-17 | Filing | |
| $20.22 | 1,862 | $37,642.75 | 18,150 | 2026-04-17 | Filing | |
| $20.22 | 9,550 | $193,065.67 | 462,577 | 2026-04-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,795,897 | $76,411,406 | 0% | |
| 2. | 2,808,583 | $56,536,776 | 0.01% | |
| 3. | 1,830,467 | $36,847,301 | 0% | |
| 4. | 1,264,023 | $25,444,783 | 0.81% | |
| 5. | 805,762 | $16,219,989 | 0.79% |
News See All
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results
TheFly reported on January 29 that TD Cowen analyst Stacy Ku raised its price target on KALV to $35 from $30 and maintained a Buy rating.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects
Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) is one of the best breakout stocks to invest in.
10 Best Breakout Stocks to Invest In
The US stock market is running high, hitting record highs, bolstered in part by continued optimism around artificial intelligence.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to KalVista Pharmaceuticals' 2025 Third Quarter Financial Update and Operating Results Conference Call.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call Transcript September 11, 2025KalVista Pharmaceuticals, Inc. misses on earnings expectations.
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista Pharmaceuticals, Inc.
10 Stocks With Huge Catalysts on the Horizon
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts.
Hedge Fund Resource Center